Olr223 inhibitors represent a unique class of chemical compounds that specifically target and modulate the activity of the Olr223 receptor, which is part of the olfactory receptor family in mammals. Olfactory receptors, including Olr223, are G-protein-coupled receptors (GPCRs) that play a significant role in the detection of odor molecules and the initiation of olfactory signal transduction pathways. These receptors are characterized by their seven transmembrane domains, which span the cell membrane and are responsible for transmitting extracellular signals to the intracellular environment. Olr223 inhibitors interact with the receptor by binding to specific sites, thereby preventing the activation of the receptor by its natural ligands. This inhibition can occur through competitive or non-competitive mechanisms, depending on the nature of the inhibitor and its binding affinity.
The study of Olr223 inhibitors is particularly relevant in the context of understanding olfactory signaling mechanisms and the broader GPCR signaling pathways. These inhibitors are often used as molecular tools to dissect the functional roles of Olr223 in various biological processes, especially those related to chemosensation and olfactory perception. By selectively inhibiting Olr223, researchers can explore the receptor's contributions to the detection and discrimination of odorants, as well as its involvement in more complex sensory processing. Additionally, Olr223 inhibitors provide insights into the structural dynamics of the receptor, helping to elucidate the conformational changes that occur upon ligand binding and inhibition. Understanding these molecular interactions at a detailed level is crucial for advancing knowledge in sensory biology, receptor-ligand interactions, and the intricate networks that govern signal transduction in olfactory systems.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING | 
|---|---|---|---|---|---|---|
| Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $127.00 $178.00 | 2 | |
| VEGFR inhibitor, potentially influences angiogenesis pathways intersecting with Olr223 signaling. | ||||||
| Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
| Dual EGFR and HER2 inhibitor, may alter pathways that indirectly modulate Olr223's activity. | ||||||
| Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
| Inhibitor of VEGFR, EGFR, and RET kinases, could affect pathways related to Olr223's function. | ||||||
| Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
| CDK4/6 inhibitor, potentially impacts cell cycle pathways that intersect with Olr223 signaling. | ||||||
| Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
| MEK inhibitor, may modulate MEK/ERK pathway influencing Olr223. | ||||||
| AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $172.00 $964.00 | 2 | |
| Multi-targeted kinase inhibitor, could affect various signaling pathways associated with Olr223. | ||||||
| Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
| mTOR inhibitor, potentially modulates Olr223 via the mTOR pathway. | ||||||
| Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
| MEK inhibitor, might impact pathways related to Olr223's signaling network. | ||||||
| Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
| EGFR inhibitor, could indirectly influence Olr223 through EGFR pathway modulation. | ||||||
| INCB28060 | 1029712-80-8 | sc-364510 sc-364510A | 10 mg 50 mg | $305.00 $750.00 | ||
| MET inhibitor, may influence signaling pathways that intersect with Olr223's function. | ||||||